Romero-Moreno JR, Ramírez-Villafaña M, González-Ponce F, Díaz-Rizo CV, Araújo-López A, Rodríguez-Hernández TM, Huerta-Viera M, González-López L

Idioma: Español
Referencias bibliográficas: 35
Paginas: 116-123
Archivo PDF: 233.50 Kb.

RESUMEN

El síndrome metabólico (SM) es una entidad caracterizada por la presencia conjunta de obesidad, dislipidemias, resistencia a la insulina e hipertensión arterial sistémica. El lupus eritematoso sistémico (LES) es una enfermedad autoinmune que se caracteriza por un proceso inflamatorio crónico que puede presentar complicaciones multisistémicas. La principal causa de mortalidad se relaciona con enfermedades cardiovasculares. En pacientes con LES, se presentan alteraciones en diversos componentes del SM, incluyendo dislipidemias, resistencia a la insulina y mayor tasa de sobrepeso/obesidad. El incremento en la frecuencia de SM en estos pacientes está asociado a factores inmunológicos, inflamatorios y farmacológicos. La frecuencia de SM en LES es de 25.6 a 86.6%. Los tratamientos utilizados en pacientes con SM en LES se basan en la terapia farmacológica con administración de antimaláricos, corticosteroides, inmunosupresores, antihipertensivos, hipoglucemiantes e hipolipemiantes y modificaciones en estilo de vida, incluyendo cambios en los hábitos de alimentación e incremento de la actividad física, ya que éstos intervienen en el control de hiperglucemias, manejo de dislipidemias y disminución del peso corporal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice. 2014; 2014 (1): 1-22.

2. Wacher-Rodarte N. Epidemiología del síndrome metabólico. Gac Méd Méx. 2009; 145 (5): 384-391.

3. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales.

4. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285 (24): 86-97.

5. Bello B, Sánchez G, Campos A, Báez E et al. Síndrome metabólico: un problema de salud con múltiples definiciones. Rev Méd Electrón. 2012; 34 (2): 199-213.

6. Parker B, Urowitz MB, Gladman DD, Lunt M , Bae SC, Sanchez-Guerrero J et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013; 72: 1308-1314.

7. Negrón AM, Molina MJ, Mayor AM, Rodriguez VE, Vilá LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008; 17 (4): 348-354.

8. Curtis LG, Smith PB, Mendez-Fernandez YV, Wilhelm AJ, Musi Ye A, Major AS. Autoinmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus. Am J Physiol Endocrinol Metab. 2012; 303 (11): 313-324.

9. Pereira J, Luna R, Gomes L, Duarte S, Leite L, da Trindade AK et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermarol. 2014; 89 (1): 118-125.

10. Anaya JM, Shoenfeld Y, Cervera R. Systemic lupus erythematosus 2014. Autoimmune Diseases. 2014; 2014: 1-2.

11. Peláez- Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyel J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. The Journal of Rheumatology. 2011; 38 (86): 3-8.

12. Enríquez-Mejía MG. Fisiopatología del lupus eritematoso sistémico. Revista de Medicina e Investigación. 2013; 1 (1): 8-16.

13. Morales-Romero J, Cázares-Méndez JM, Gámez-Nava JI, Triano-Páez M et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1 (2): 87-94.

14. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010; 36 (1): 81-97.

15. El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al. Hyperinsulinemia, insulin resistance, and circulcating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006; 33 (1): 50-56.

16. Wijaya LK, Kaskmir YI, Sukmana N, Subetki I et al. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones-Indones J Intern Med. 2005; 37 (3): 132-144.

17. Cadaval RAM, Martinez JE, Mazzolin MA, Barros RGT et al. Assessment of the risk of coronary heart disease in women with systemic lupus erythematosus. Bras J Rheumatol. 2009; 49 (6): 658-669.

18. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66: 208-214.

19. Toloza S, Uribe A, McGwin G, Alarcon G, Fessler B, Bastian H et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Arthritis & Rheumatism. 2004; 50 (12): 3947-3957.

20. Ormseth MJ, Swift LL, Fazio S, Linton MF, Raggi P, Solus JF et al. Free fatty acids are associated with metabolic syndrome and insulin resistance, but not inflammation in SLE patients. Lupus. 2013; 22 (1): 26-33.

21. Oeser A, Chung CP, Ananuma Y, Avalos I, Stein M. Obesity is an independent contributor functional capacity and inflammation in systemic lupus erythematosus. Arthritis & Rheumatism. 2005; 52 (11): 3651-3659.

22. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008; 58 (7): 2105-2112.

23. Parker B, Ahmad Y, Sherlmerdine J, Edlin H, Yates AP, Teh L et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus. 2011; 20: 1459-1465.

24. Pagano G, Bruno A, Cavallo-Perin P, Cesco L, Imbimbo B. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone. Arch Intern Med. 1989; 149 (5): 1089-1101.

25. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relatioship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002; 40 (1): 937-943.

26. Shinjo SK, Bonfa E, Wojdyla D, Borba EF et al. Antimalarial treatment may have a time- dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010; 62: 855-862.

27. VanHalm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther. 2006; 8: R151.

28. Maiz A. El síndrome metabólico y riesgo cardiovascular. Boletín de la Escuela de Medicina. 2005; 30 (1): 1-6.

29. Escott-Stump S. Nutrición, diagnóstico y tratamiento. 6a ed. Wolters Kluwer: Lippincott Williams & Wilkins; 2008.

30. Minami Y. Diet and systemic lupus erythematosus: a 4 year prospective study Japanese patients. J Rheumatol. 2003; 30: 747.

31. Shah M. Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program. J Rheumatol. 2004; 31: 71.

32. Simopoulos A. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21: 495.

33. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk Factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93 (5): 513-519.

34. Rhaman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001; 10(2): 93-96.

35. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005; 14 (9): 683-686.